Neovacs -- Paris, October 22, 2009 -- Neovacs, a biotechnology company developing proprietary
immunotherapeutics for autoimmune and chronic diseases, today released a summary of
preclinical results achieved with its Interferon alpha (IFNa) Kinoid immunotherapy for lupus, as
presented in a poster at the ACR/ARHP 2009 Annual Scientific Meeting (October 17th-21st in
Philadelphia).
